280 related articles for article (PubMed ID: 35158020)
41. DUX4-Induced Histone Variants H3.X and H3.Y Mark DUX4 Target Genes for Expression.
Resnick R; Wong CJ; Hamm DC; Bennett SR; Skene PJ; Hake SB; Henikoff S; van der Maarel SM; Tapscott SJ
Cell Rep; 2019 Nov; 29(7):1812-1820.e5. PubMed ID: 31722199
[TBL] [Abstract][Full Text] [Related]
42. MRI-informed muscle biopsies correlate MRI with pathology and DUX4 target gene expression in FSHD.
Wang LH; Friedman SD; Shaw D; Snider L; Wong CJ; Budech CB; Poliachik SL; Gove NE; Lewis LM; Campbell AE; Lemmers RJFL; Maarel SM; Tapscott SJ; Tawil RN
Hum Mol Genet; 2019 Feb; 28(3):476-486. PubMed ID: 30312408
[TBL] [Abstract][Full Text] [Related]
43. Overexpression of the double homeodomain protein DUX4c interferes with myofibrillogenesis and induces clustering of myonuclei.
Vanderplanck C; Tassin A; Ansseau E; Charron S; Wauters A; Lancelot C; Vancutsem K; Laoudj-Chenivesse D; Belayew A; Coppée F
Skelet Muscle; 2018 Jan; 8(1):2. PubMed ID: 29329560
[TBL] [Abstract][Full Text] [Related]
44. DUX4 expressing immortalized FSHD lymphoblastoid cells express genes elevated in FSHD muscle biopsies, correlating with the early stages of inflammation.
Banerji CRS; Panamarova M; Zammit PS
Hum Mol Genet; 2020 Aug; 29(14):2285-2299. PubMed ID: 32242220
[TBL] [Abstract][Full Text] [Related]
45. Muscle pathology from stochastic low level DUX4 expression in an FSHD mouse model.
Bosnakovski D; Chan SSK; Recht OO; Hartweck LM; Gustafson CJ; Athman LL; Lowe DA; Kyba M
Nat Commun; 2017 Sep; 8(1):550. PubMed ID: 28916757
[TBL] [Abstract][Full Text] [Related]
46. Facioscapulohumeral muscular dystrophy: consequences of chromatin relaxation.
van der Maarel SM; Miller DG; Tawil R; Filippova GN; Tapscott SJ
Curr Opin Neurol; 2012 Oct; 25(5):614-20. PubMed ID: 22892954
[TBL] [Abstract][Full Text] [Related]
47. Deciphering transcription dysregulation in FSH muscular dystrophy.
Ehrlich M; Lacey M
J Hum Genet; 2012 Aug; 57(8):477-84. PubMed ID: 22718021
[TBL] [Abstract][Full Text] [Related]
48. Sporadic DUX4 expression in FSHD myocytes is associated with incomplete repression by the PRC2 complex and gain of H3K9 acetylation on the contracted D4Z4 allele.
Haynes P; Bomsztyk K; Miller DG
Epigenetics Chromatin; 2018 Aug; 11(1):47. PubMed ID: 30122154
[TBL] [Abstract][Full Text] [Related]
49. Human miRNA miR-675 inhibits DUX4 expression and may be exploited as a potential treatment for Facioscapulohumeral muscular dystrophy.
Saad NY; Al-Kharsan M; Garwick-Coppens SE; Chermahini GA; Harper MA; Palo A; Boudreau RL; Harper SQ
Nat Commun; 2021 Dec; 12(1):7128. PubMed ID: 34880230
[TBL] [Abstract][Full Text] [Related]
50. Facioscapulohumeral muscular dystrophy.
Tawil R
Handb Clin Neurol; 2018; 148():541-548. PubMed ID: 29478599
[TBL] [Abstract][Full Text] [Related]
51. Transcriptional and cytopathological hallmarks of FSHD in chronic DUX4-expressing mice.
Bosnakovski D; Shams AS; Yuan C; da Silva MT; Ener ET; Baumann CW; Lindsay AJ; Verma M; Asakura A; Lowe DA; Kyba M
J Clin Invest; 2020 May; 130(5):2465-2477. PubMed ID: 32250341
[TBL] [Abstract][Full Text] [Related]
52. RNA interference inhibits DUX4-induced muscle toxicity in vivo: implications for a targeted FSHD therapy.
Wallace LM; Liu J; Domire JS; Garwick-Coppens SE; Guckes SM; Mendell JR; Flanigan KM; Harper SQ
Mol Ther; 2012 Jul; 20(7):1417-23. PubMed ID: 22508491
[TBL] [Abstract][Full Text] [Related]
53. Nuclear bodies reorganize during myogenesis in vitro and are differentially disrupted by expression of FSHD-associated DUX4.
Homma S; Beermann ML; Yu B; Boyce FM; Miller JB
Skelet Muscle; 2016 Dec; 6(1):42. PubMed ID: 27906075
[TBL] [Abstract][Full Text] [Related]
54. Identification of candidate miRNA biomarkers for facioscapulohumeral muscular dystrophy using DUX4-based mouse models.
Nunes AM; Ramirez M; Jones TI; Jones PL
Dis Model Mech; 2021 Aug; 14(8):. PubMed ID: 34338285
[TBL] [Abstract][Full Text] [Related]
55. WDR5 is required for DUX4 expression and its pathological effects in FSHD muscular dystrophy.
Mocciaro E; Giambruno R; Micheloni S; Cernilogar FM; Andolfo A; Consonni C; Pannese M; Ferri G; Runfola V; Schotta G; Gabellini D
Nucleic Acids Res; 2023 Jun; 51(10):5144-5161. PubMed ID: 37021550
[TBL] [Abstract][Full Text] [Related]
56. Transgenic Drosophila for Investigating DUX4 and FRG1, Two Genes Associated with Facioscapulohumeral Muscular Dystrophy (FSHD).
Jones TI; Parilla M; Jones PL
PLoS One; 2016; 11(3):e0150938. PubMed ID: 26942723
[TBL] [Abstract][Full Text] [Related]
57. p53-independent DUX4 pathology in cell and animal models of facioscapulohumeral muscular dystrophy.
Bosnakovski D; Gearhart MD; Toso EA; Recht OO; Cucak A; Jain AK; Barton MC; Kyba M
Dis Model Mech; 2017 Oct; 10(10):1211-1216. PubMed ID: 28754837
[TBL] [Abstract][Full Text] [Related]
58. Loss of epigenetic silencing of the DUX4 transcription factor gene in facioscapulohumeral muscular dystrophy.
Hewitt JE
Hum Mol Genet; 2015 Oct; 24(R1):R17-23. PubMed ID: 26113644
[TBL] [Abstract][Full Text] [Related]
59. Muscle xenografts reproduce key molecular features of facioscapulohumeral muscular dystrophy.
Mueller AL; O'Neill A; Jones TI; Llach A; Rojas LA; Sakellariou P; Stadler G; Wright WE; Eyerman D; Jones PL; Bloch RJ
Exp Neurol; 2019 Oct; 320():113011. PubMed ID: 31306642
[TBL] [Abstract][Full Text] [Related]
60. Membrane Repair Deficit in Facioscapulohumeral Muscular Dystrophy.
Bittel AJ; Sreetama SC; Bittel DC; Horn A; Novak JS; Yokota T; Zhang A; Maruyama R; Rowel Q Lim K; Jaiswal JK; Chen YW
Int J Mol Sci; 2020 Aug; 21(15):. PubMed ID: 32759720
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
